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Intravesical Application of Lidocaine and Sodium Bicarbonate in
the Treatment of Obstructive Idiopathic Lower Urinary Tract
Disease in Cats
L. Zezza, C.E. Reusch, and B. Gerber
Background: In human patients with interstitial cystitis, intravesical instillation of alkalinized lidocaine sometimes is
associated with sustained amelioration of symptoms beyond the acute treatment phase. Interstitial cystitis shares many fea-
tures in common with feline idiopathic cystitis.
Objective: To evaluate whether intravesical instillation of alkalinized lidocaine decreases recurrence of urethral obstruc-
tion and severity of clinical signs in cats with obstructive idiopathic LUTD.
Animals: Twenty-six cats with obstructive idiopathic LUTD. Twelve cats in case group (treatment with alkalinized
lidocaine) and 14 control cats (treatment with placebo or standard treatment).
Methods: Cats were randomly assigned to treatment (2 or 4 mg/kg lidocaine and sodium bicarbonate) or placebo
groups (0.2 mL/kg saline solution and sodium bicarbonate). The intravesical instillation was done once a day for 3 days.
Some cats underwent standard treatment only (indwelling urinary catheter for 3 days without intravesical instillations). A
2-week, 1-month, and 2-month follow-up after treatment was made using a questionnaire. The recurrence rate and amelio-
ration scores of clinical signs were assessed and compared.
Results: Recurrence of urethral obstruction was 58% (7/12) in the case group and 57% (8/14) in the control group.
Amelioration scores were similar between the 2 groups.
Conclusion and Clinical Importance: Intravesical administration of lidocaine for up to 3 consecutive days had no appar-
ent beneficial effect on decreasing recurrence rate and severity of clinical signs in cats with obstructive idiopathic LUTD.
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The term feline lower urinary tract disease (LUTD)has been used to describe clinical signs related to
irritative voiding, but does not identify the underlying
etiology.1,2 The possible causes can include bacterial
urinary tract infection, trauma, urolithiasis, urethral
plugs, neoplasia, anatomic malformation, behavioral
disorders, and neurologic problems.1,3 If no specific
reason is found, the disease is called idiopathic.4
Regardless of etiology, the resultant clinical signs are
similar and include dysuria, stranguria, hematuria,
pollakiuria, and periuria.2,5 The disorder can be
obstructive, and urethral obstruction was reported to
occur more commonly in young cats and almost exclu-
sively in male cats because of their relatively long and
narrow urethra.1
Recurrence of obstruction is common. In 1 study, it
was reported that 8 of 22 cats (36%) with idiopathic
urethral obstruction reobstructed after a median of
17 days.6 In a more recent study, 11 of 55 cats (22%)
with idiopathic obstructive LUTD experienced at least
1 recurrence in the 6 months after a previous episode.7
Currently, no treatment is known to decrease these
high recurrence rates.
A syndrome in human beings, known as interstitial
cystitis (IC), shares many features in common with
cats that have idiopathic cystitis.8 The cause of IC also
is unknown, and treatment is mostly empirical and
unsatisfactory.9 In a recent manufacturer funded
study, treatment with intravesical alkalinized lidocaine
(PSD597) and sodium bicarbonate in patients with IC
was reported to provide amelioration of symptoms
beyond the acute treatment phase.10 IC is thought, in
part, to develop into a visceral allodynia, as a result of
sensitized local bladder afferent nerves.11 Theoretically,
intravesical administration of the local anesthetic lido-
caine could help control the pain and inflammation
associated with IC, returning the neuropathic bladder
to a more normal state with time.10
Because of the positive effects of intravesical alkalin-
ized lidocaine in affected humans, and the similarities
reported between human IC and idiopathic LUTD in
cats, we hypothesized that cats with LUTD might also
benefit from intravesical lidocaine instillation. Because
obstructive LUTD can become life threatening and
urinary catheterization is necessary to relieve the
obstruction, the study was only conducted on cats with
urethral obstruction. The aim of this prospective study
was to determine whether the intravesical instillation
of lidocaine could effectively decrease the severity of
clinical signs or the recurrence rate of urethral obstruc-
tion in cats with obstructive idiopathic LUTD.
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Materials and Methods
Case Selection
Cats presented to the Clinic for Small Animal Internal Medi-
cine, University of Zurich, between July 2010 and September
2011 showing ! 1 of the following clinical signs, pollakiuria,
hematuria, dysuria, stranguria, inappropriate urination, and with
partial or complete urethral obstruction, were considered for the
study. A cat was regarded as obstructed if the bladder was dis-
tended and the cat was unable to void urine freely or only voided
drops of urine.
Diagnostic investigation included history from the owner
regarding previous episodes of LUTD and observed clinical
abnormalities, a physical examination, urinalysis, urine culture,
hematology, serum biochemistry profile, radiographs of the abdo-
men (care was taken to include the entire lower urinary tract to
the tip of the penis), and ultrasound examination of the urogeni-
tal tract. Urine was collected by cystocentesis or by catheteriza-
tion. Qualitative urine culture was performed on sheep blood
agar, Gassner agar, and Clad agar.a If there was suspicion of
urethral stricture or perforation of the lower urinary tract, con-
trast radiography (retrograde uretrography) also was performed.
Urolithiasis was diagnosed when calculi were seen on radio-
graphs or during ultrasound examination of the urinary tract.
Urinary tract infection was diagnosed when qualitative urine cul-
ture was positive. Urethral plug was diagnosed when a plug was
identified during urethral catheterization. If the underlying cause
of the obstruction could not be identified after appropriate
evaluation, idiopathic LUTD was diagnosed. Only cats with the
idiopathic LUTD were enrolled in the study. Owner consent was
obtained before treatment with lidocaine. The government animal
welfare authorities of the canton of Zurich, Switzerland approved
the treatment protocol used in the study.
Procedure
After diagnostic investigation and confirmation of urethral
obstruction, IV fluid therapy was started. Urethral obstruction
was relieved in a standard manner. Cats were anesthetized with
fentanylb (5 lg/kg IV) and midazolamc (0.23 mg/kg IV) or
ketamined (10 mg/kg IV [for anesthetic induction] or IM [for
deep sedation]) and midazolam (0.1 mg/kg IV or IM) and main-
tained under anesthesia with IV injection of propofole or with
inhalation anesthesia (isofloranf) until an indwelling urinary cath-
eterg was placed and sutured to the prepuce. When feasible, the
urinary catheter was kept in place for 3 days. The urinary cathe-
ter was connected to a sterile closed collection systemh to keep
the bladder empty and to quantify urine production. Cats were
concurrently treated with an analgesic (buprenorphinei 0.006–
0.014 mg/kg IV q6h) and fluid was administered IV (lactated
Ringer’s solution or 0.9% saline solution).j The initial infusion
rate was determined based on the hydration status and physical
condition of the cat at presentation. The rate was adjusted daily
based on urine production assessed during the day.
The first 12 cats were treated by intravesical lidocaine instilla-
tion,k 0.1 mL/kg of a 2% lidocaine solution, a dosage reported
to be safe after IV administration in a recent study.12 Sodium
bicarbonate,l 0.06 mL/kg of an 8.4% solution, was added imme-
diately afterward. Because no adverse effects were seen and serum
concentrations were low, we increased the amount of lidocaine in
the solution. Subsequently, the next cats were randomly assigned
to receive intravesical either 0.2 mL/kg of a 2% lidocaine solu-
tion or placebo (0.2 mL/kg of a 0.9% saline solution) and
0.06 mL/kg of an 8.4% sodium bicarbonate solution, respec-
tively. If the owners declined to enroll their cats in the study or if
the cats were too aggressive and uncooperative in the beginning
of treatment, the cats were treated according to a standard proce-
dure (3 days with an indwelling urinary catheter but without
intravesical instillation).
The case group consisted of cats that received the intravesical
medication of either 0.1 or 0.2 mL/kg of a 2% lidocaine solution
and 0.06 mL/kg of an 8.4% sodium bicarbonate solution. The
control group consisted of cats that either received intravesical
instillation of 0.2 mL/kg placebo (equal to the volume of the
instilled 2% lidocaine solution) and 0.06 mL/kg of an 8.4%
sodium bicarbonate solution or those that underwent the stan-
dard treatment. Before instillation, the bladder was emptied and
after instillation, the urinary catheter was closed for 1 hour to
allow the medication to remain in place. After 1 hour, the cathe-
ter was reattached to the closed urine collection system and urine
production was assessed. This procedure was performed once a
day for a maximum of 3 consecutive days.
After removal of the urinary catheter, presence of spontaneous
urination was assessed by monitoring the cats every 2 hours for
up to 2 days. Antibacterial treatment with amoxicillin-clavulanic
acidm (20 mg/kg PO q12h) or amoxicillinn (20 mg/kg PO q12h)
was started concurrently and continued in cats that did not
reobstruct immediately after removal of the urinary catheter.
Treatment success was defined as spontaneous urination (nor-
mal urine stream and empty bladder after voiding) and discharge
from the hospital. Buprenorphine (0.006–0.014 mg/kg PO q8h)
or meloxicam suspensiono (0.025 mg/kg PO q24h) in cats with
and without azotemia at presentation, respectively, was pre-
scribed for 3 additional days after discharge. The antibacterial
treatment was continued for 1 week. Follow-up of cats with
successful treatment was made 2 weeks, 1 month, and 2 months
after discharge using a questionnaire to assess the severity of the
clinical signs after treatment.
Treatment failure was defined as failure to have spontaneous
urination (ie, unable to urinate or only voiding drops of urine
with a distended bladder). These cats were excluded from follow-
up assessment. Their owners were asked to complete only the
questionnaire for the clinical signs before treatment. A modifica-
tion of a previously used questionnaire13 was used. All question-
naires were composed of 8 visual analog scales, each 10 cm in
length, with values ranging from 0 (normal cat) to 10 (very severe
clinical signs). The 8 signs that owners were asked to record
were (1) increased frequency of urination, (2) straining while uri-
nating, (3) crying out while urinating, (4) presence of blood in
the urine (macroscopic hematuria), (5) urination outside the litter
box, (6) increased grooming around the perineum, (7) altered
behavior (increased aggression, fear, or nervousness), and (8)
gastrointestinal symptoms (eg, vomiting, diarrhea).
The primary endpoint was the recurrence of urethral obstruc-
tion within 2 months after removal of the catheter. The recur-
rence rate between groups was assessed and compared.
A secondary endpoint included the assessment of changes in
severity (amelioration) of clinical signs of LUTD from baseline
(before treatment), 2 weeks, 1 month, and 2 months after dis-
charge in cats with successful treatment. Because of the subjectiv-
ity of the questionnaire, the median change from baseline
(median amelioration scores) for individual clinical signs and the
sum of the 8 scales were calculated at each time point. Differ-
ences between the groups were compared. The questionnaire for
the time before treatment was performed before or at least on
the same day of discharge.
Serum Lidocaine Concentrations and Tolerability
Blood samples for the evaluation of plasma lidocaine concen-
trations were collected from 2 cats treated with 0.1 mL/kg of 2%
lidocaine and 2 cats treated with 0.2 mL/kg of 2% lidocaine at
time 0 h (immediately after instillation), 0.5, 1, 2, and 3 h after
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treatment on 2 consecutive days of treatment. Plasma lidocaine
concentrations were measured using high performance liquid
chromatography-mass spectrometry. Any clinical signs of adverse
effects related to lidocaine toxicity were monitored and recorded
every 2 hours during hospitalization.
Statistical Analysis
Results were analyzed using a commercial computer program
(Statistical Package for Social Science 8.0; SPSS). Because of the
small sample size, especially in the follow-up assessment, compar-
isons of variables within and among groups were performed
using a nonparametric test (the Mann–Whitney U-test). Statisti-
cal analysis was not conducted if <4 results were available to
compare. Differences were considered significant at P < .05.
Results
Overall, 69 cats were presented to the Clinic for
Small Animal Internal Medicine, University of Zurich
between July 2010 and September 2011 because of
lower urinary tract signs with urethral obstruction.
Thirty-four cats were excluded from the study because
of urolithiasis (=13, 19%), urethral plugs (=5, 7%),
and urinary tract infection (=14, 20%). In 2 cats (3%),
a definitive diagnosis was not possible because not all
the diagnostic investigations could be made. These 2
cats were also excluded from the study. In 35 cats
(51%), no specific cause for the clinical signs could
be identified. These cats were classified as having
idiopathic obstructive LUTD. Of these 35 cats, 9 were
excluded because of immediate surgery (perineal ureth-
rostomy, 6 cats), urethral perforation after catheteriza-
tion (1 cat), and euthanasia requested by the owner (2
cats). Twenty-six cats (38%) remained in the study.
The cats included in the study ranged in age from 1
to 9 years (median, 5 years) and weighed between 3.8
and 7.2 kg (median, 5.5 kg). There were 25 neutered
males and 1 intact male. The breeds included 20
domestic cats, 2 Persians, 1 Main Coon, 1 Siamese,
and 2 Siberian Forest cats. Blood urea nitrogen
(BUN) serum, creatinine, and serum potassium
concentration ranged between 5.5 and 138 mmol/L
(median, 12.6 mmol/L), 70 and 1,700 lmol/L (median,
150.5 lmol/L), and 2.8 and 8.6 mmol/L (median,
4.5 mmol/L), respectively. The present episode was the
1st known episode of LUTD for 21 cats whereas
recurrent bouts were described for the 5 other cats.
Twelve cats were treated with 2% lidocaine (4 cats
with 0.1 mL/kg and 8 cats with 0.2 mL/kg). Fourteen
cats were in the control group (8 cats were treated with
placebo and 6 cats with standard treatment). There
was no significant difference in age, breed, BUN
serum, creatinine, serum potassium concentration, or
number of LUTD episodes between groups. Body
weight was significantly higher in the case group
(P = .04). Clinical signs scores available from 10 cats
in the case group and 12 cats in the control group
before treatment were not significantly different
between the 2 groups (Table 1). In 3 cats treated with
0.2 mL/kg 2% lidocaine and in 1 cat treated with pla-
cebo, intravesical instillation was possible only for
2 days because of self-removal of the catheter after
2 days of treatment. In 1 cat treated with 0.2 mL/kg
2% lidocaine, intravesical treatment was possible only
for 1 day because of the aggressive behavior of the cat
after the 1st day of treatment. Median treatment dura-
tion in both groups was 3 days. All the cats experi-
enced post-obstructive diuresis after relief of
obstruction. In 24 cats, the highest daily urine produc-
tion was assessed, and ranged between 2.2 and
12.0 mL/kg/h (median, 6 mL/kg/h). Additionally, in 5
of the 26 cats, urine pH was measured at 1 hour
immediately before reattaching the urinary catheter to
the collection system. Urine pH was 6, 7.5, 8.5 in 3
cats, and 8 in other 2 cats.
Recurrence of urethral obstruction after removal of
the urethral catheter was 58% (7/12) in the case group,
50% (2/4) in cats that received 0.1 mL/kg 2% lido-
caine, 63% (5/8) in cats that received 0.2 mL/kg 2%
lidocaine within 1–14 days (median, 3 days), and 57%
(8/14) in the control group (63% in 5/8 cats in the pla-
cebo group and 50% in 3/6 cats that received standard
treatment) within 1–2 days (median, 1 day). Five cats
in the case group and 6 cats in the control group had
successful treatment for at least 2 months after dis-
charge. These 11 cats were followed up for assessment
of amelioration of clinical signs. Of all 11 question-
naires sent to the owners at each of 3 time points
(2 weeks, 1 month, and 2 months after discharge), 10
(4 of the case group and 6 of the control group), 10 (4
of the case group and 6 of the control group), and 9
(4 of the case group and 5 of the control group) were
returned, respectively. The owners who did not return
questionnaires were contacted by phone to assess
recurrence. In the case group, the degree of severity in
frequency of urination was not recorded in 1 question-
naire before treatment as well as in another cat
2 weeks and 2 months after treatment. For these
Table 1. Median and range of the clinical signs score
before treatment (baseline score) in the case (10 cats)
and in the control group (12 cats).
Clinical Signs Group Baseline
Increased frequency of urination Case 5 (1–10)
Control 8 (0–10)
Straining while urinating Case 7.5 (1–10)
Control 7 (1–10)
Crying out while urinating Case 0 (0–8)
Control 1 (0–10)
Presence of blood in the urine Case 1 (0–10)
Control 1 (0–10)
Urination outside the litter box Case 8 (0–10)
Control 7 (0–10)
Increased grooming around the perineum Case 6 (2–10)
Control 7 (0–10)
Altered behavior Case 5.5 (0–10)
Control 6.5 (0–10)
Gastrointestinal symptoms Case 1.5 (0–10)
Control 1 (0–10)
Sum Case 39 (14–51)
Control 43 (9–75)
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clinical signs, 2 weeks and 2 months after treatment,
the available results were insufficient to allow statistical
analysis.
Cats treated with lidocaine showed significantly
higher median amelioration score in straining 2 weeks
after discharge compared to the cats in the control
group (P = .01). There were no significant differences
between groups in the other individual clinical signs as
well as in the sum of the scores at any time point.
Serum Lidocaine Concentrations and Tolerability
In all cats, lidocaine concentrations peaked within
60 minutes of instillation, ranging between 0.45 and
4.1 lmol/L (Table 2). In all 4 cats, blood sampling
was not possible at all 5 time points. No severe
adverse events were reported during intravesical ther-
apy. One cat treated with 0.2 mL/kg 2% lidocaine
experienced 1 episode of salivation on the 3rd day of
treatment.
Discussion
The response of cats with idiopathic obstructive
LUTD to lidocaine treatment with regard to recur-
rence and amelioration of clinical signs was poor.
Within the 1-year trial period, recurrence of urethral
obstruction was seen in 58% of the cats in the case
group and in 57% of cats in the control group within
2 months. In a previous 1-year study, cats with idio-
pathic obstructive LUTD experienced a recurrence rate
of only 22% within 6 months.7 It is unclear why the
cats in the current study showed more recurrence of
the disease, and may reflect the different definition
used to describe the obstruction. In particular, in the
current study a cat was defined as obstructed if it was
unable to generate a normal stream of urine (ie, only
voided drops of urine) with a distended bladder. It
also could be that the observation of the clinicians and
the owners was closer because of the prospective study
design and led to the recognition of even mild partial
obstruction. Furthermore, idiopathic LUTD was diag-
nosed by exclusion of other possible causes and, as dis-
cussed in a previous study, a specific cause potentially
could have been overlooked. For example, a plug may
not have been seen and may have been retropulsed
into the bladder after placement of the urinary cathe-
ter, leading to a misdiagnosis of idiopathic LUTD.6
Furthermore, retrograde urethrography was only
performed when leakage of the lower urinary tract was
suspected. Anatomic malformations and strictures
could not definitively be excluded in the cats in which
urethrography was not performed.
A significant difference between groups in the fol-
low-up assessment was only observed in amelioration
of straining 2 weeks after discharge. This significance
may only be the consequence of statistical analysis
conducted for several clinical signs all reflecting the
same disease (type I SE). However, it might also reflect
a limited potential effect of lidocaine, inducing only
relief from pain while urinating (stranguria) without
inducing an adequate local anti-inflammatory effect.
Lidocaine is primarily recognized as a neuronal
sodium channel-blocking agent, but it also has propri-
eties capable of substantial antihistaminic effects. In an
in vitro study, these effects were reported to be dose-
dependent and at concentrations in the high micromo-
lar range (234–2340 lg/mL or 1,000–10,000 lmol/L,
respectively).14 A low serum lidocaine concentration
may be sufficient to generate a neuronal sodium-block-
ing effect (ie, pain relief), whereas a very high tissue
lidocaine concentration may be necessary to achieve
antihistaminic effects (ie, anti-inflammatory effect). The
lack of a demonstrable relevant beneficial effect could
be related to subtherapeutic treatment because of an
inadequate dosage of lidocaine or sodium bicarbonate,
inadequate duration of the treatment, or the small
sample size and insufficient power.
It is well known that cats may be more sensitive
than other species to the toxic effects of local anesthet-
ics, in particular to central nervous system effects.15
However, the cumulative doses of lidocaine in healthy
cats were reported to be 9.7 mg/kg at the stage of
excitation and 22.3–27.3 mg/kg for the induction of
convulsions.16 The plasma lidocaine concentration
associated with the onset of seizures was reported to
be between 71.3 and 208.5 lg/mL (304.8–891.3 lmol/
L).17 Because adverse effects also have been observed
Table 2. Plasma lidocaine concentrations (lmol/L) and post-obstructive diuresis (mL/kg/h) at 2 consecutive days
after intravesical lidocaine application in 4 cats.
Hours (h)
0.1 mL/kg 2% Lidocaine 0.2 mL/kg 2% Lidocaine
Cat I Cat II Cat III Cat IV
Day 1 Day 2 Day 2 Day 3 Day 1 Day 2 Day 1 Day 2
0 – <0.10 – 4.07 – <0.10 – –
0.5 – 1.57 2.48 2.71 0.48 0.45 0.96 1.64
1 1.34 1.45 1.36 – 0.51 – 0.93 2.46
2 – – 0.79 1.20 – 0.35 0.42 0.92
3 0.65 0.87 0.64 0.79 0.24 – 0.30 0.30
POD 4.6 4.2 6.3 5.3 6.6 6.6 8.0 7.5
POD, post-obstructive dieresis.
Highest serum lidocaine concentration of all collected blood samples per cat and day.
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after IV application of <2 mg/kg lidocaine18 and
because cats with cystitis have increased bladder per-
meability,19 the first cats of the current study were
treated with a dose of 0.1 mL/kg of a 2% lidocaine
solution. The serum lidocaine concentration was
assessed in 2 of these cats. The concentration was well
below to the plasma concentration reported to be asso-
ciated with the onset of seizures, and the cats did not
show any obvious adverse effects. Therefore, the next
cats were treated with a higher dose (0.2 mL/kg of a
2% solution) and even with this dose a critical concen-
tration was not reached. Only 1 cat showed 1 episode
of salivation on the 3rd day of the lidocaine treatment.
This cat exhibited signs of stress, and the new environ-
ment may have contributed to the salivation. Previous
studies conducted in humans demonstrated poor
absorption of lidocaine from the bladder and poor
local therapeutic effects if only applied intravesical-
ly.20,21 Enhanced absorption and therapeutic effects
were reported after alkalinizing the injected solution
with sodium bicarbonate.22,23 Therefore, a sequential
instillation of 0.06 mL/kg of an 8.4% sodium bicarbo-
nate solution was added in all the cats receiving intra-
vesical medication. However, voided bladder content
pH 1 hour after application was not alkaline in all the
5 cats in which it was measured. Furthermore, the
lidocaine concentration in serum differed considerably
among cats. A possible explanation could be the phe-
nomenon of post-obstructive diuresis (urine output
>2 mL/kg/h).24 This pathophysiologic process could
lead to dilution of urine, alteration of urine pH, and
reduction of the bladder lidocaine concentration within
1 hour after application. A longer duration of treat-
ment also may have influenced the outcome. In studies
of patients with IC, an immediate and sustained symp-
tomatic relief beyond the treatment phase was reported
after 5 consecutive days of lidocaine instillations10 as
well as after 6 instillations over 2 weeks.23 Because the
risk of physical or chemical injury to the urinary tract
and bacterial infections has been reported to increase
with the duration of catheterization,25,26 therapy in the
current study was limited to 3 days.
Important weaknesses of the study are the small
sample size, in particular in the follow-up assessment.
Furthermore, because of the uncooperative behavior of
some cats, intravesical instillation was not always possi-
ble for 3 consecutive days. Moreover, only cooperative
and nonaggressive cats as well as cats of owners who
wanted to participate were randomly assigned to the
study groups. Furthermore, because written consent by
the owners of the cats treated with lidocaine was
requested, we decided not to blind the owners to the
treatments used. These attendant circumstances could
have biased our results.
In conclusion, the current study shows an alternative
procedure for the treatment of idiopathic cystitis in cats
with urethral obstruction. The results suggest that in-
travesical administration of lidocaine (0.1 or 0.2 mL/kg
of a 2% solution) and sodium bicarbonate (0.06 mL/kg
of an 8.4% solution) for 3 consecutive days does not
have apparent beneficial effects on decreasing the recur-
rence of obstruction as well as on clinical signs in cats
with idiopathic obstructive LUTD.
Footnotes
a Oxoid, Pratteln, Switzerland
b Sintenyl, Sintetica SA, Mendrisio, Switzerland
c Dormicum, Roche Pharma (Switzerland) AG, Reinach, Switzer-
land
d Narketan10, Ve´toquinol AG, Ittingen, Switzerland
e Propofol 1% MCT Fresenius, Fresenius Kabi (Switzerland)
AG, Stans, Switzerland
f Abbott AG, Baar, Switzerland
g PortexJackson Cat Catheter; Smiths Medical International Ltd,
UK/SlipperySam Tomcat Urethral Catheter; Smiths Medical
PM Inc, Waukesha, WI
h Urotube20; B. Braun Medical Meslungen GA, Melsungen,
Germany
i Temgesic; Reckitt Benckiser Healthcare Ltd, UK
j Fresenius Kabi GmbH, Hamburg, Germany
k Lidocain HCL 2%; Kantonapotheke Zurich, Switzerland
l B.Braun Medical AG, Sempach, Switzerland
m Clavubactin; Dr E.Graeub AG, Bern, Switzerland
n Amoxicat40; Biokema SA, Crissier-Lausanne, Switzerland
o Metacam; Boehringer Ingelheim (Switzerland) GmbH, Basel,
Switzerland
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